These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18511159)

  • 1. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
    Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D
    Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.
    Thérien A; Bédard M; Carignan D; Rioux G; Gauthier-Landry L; Laliberté-Gagné MÈ; Bolduc M; Savard P; Leclerc D
    J Nanobiotechnology; 2017 Jul; 15(1):54. PubMed ID: 28720097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of immunity induced by M2e of influenza virus.
    Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
    Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
    Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
    Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonosoff GP; Ravin NV
    BMC Biotechnol; 2015 May; 15():42. PubMed ID: 26022390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
    Wu F; Yuan XY; Li J; Chen YH
    Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].
    Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D
    Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses.
    Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D
    Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP.
    Babin C; Majeau N; Leclerc D
    J Nanobiotechnology; 2013 Apr; 11():10. PubMed ID: 23556511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
    Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
    Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel M2e based flu vaccine formulation for dogs.
    Leclerc D; Rivest M; Babin C; López-Macias C; Savard P
    PLoS One; 2013; 8(10):e77084. PubMed ID: 24098576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.